Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies
characterized by abnormal proliferation of immature lymphoid cells. It is the most commonly …

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, arising from
immature lymphocytes that show uncontrolled proliferation and arrested differentiation …

Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions of
relapsed/refractory B-acute lymphoblastic leukemia (ALL). However, case reports suggested …

While next‐generation sequencing technologies provide excellent strategies to screen for
newly defined genetic abnormalities of prognostic or therapeutic significance in patients with …

Abstract Cytokine Receptor-Like Factor 2 (CRLF2) overexpression occurs in 5-15% of B-cell
precursor acute lymphoblastic leukaemia (B-ALL). In∼ 50% of these cases, the mechanisms …

Background ABL-class fusions including NUP214-ABL1 and EBF1-PDGFRB occur in high
risk acute lymphoblastic leukaemia (ALL) with gene expression patterns similar to BCR-ABL …

Background The prognostic significance of cytokine receptor-like factor 2 (CRLF2)
overexpression in pediatric B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) is …

Copy number variations (CNVs) are widespread in both pediatric and adult cases of B-cell
acute lymphoblastic leukemia (B-ALL); however, their clinical significance remains unclear …

Abstract Purpose BCR:: ABL1-like pre-B-ALL comprises a myriad of genetic lesions making
molecular diagnosis challenging and expensive. Its frequency and outcome are less studied …

Introduction Worldwide, the B‐cell precursor acute lymphoblastic leukaemia (BCP‐ALL)
treatment protocols are based on risk‐adaptive therapy, that is on the search for biological …